BioTelemetry (BEAT) Tops Q1 EPS by 2c; Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
BioTelemetry, Inc. Reports First Quarter 2020 Financial Results
May 6, 2020 4:05 PM EDTMALVERN, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended March 31, 2020.
Quarter Highlights
Recognized quarterly revenue of $113.0 millionReached 8.7% year-over-year quarterly revenue growthAchieved 31st consecutive quarter of year-over-year revenue growthReported quarterly GAAP net income of $7.1 million, or 6.3% of revenueRealized quarterly adjusted EBITDA of $29.5 million, or 26.1% of revenue... More